Six-Gene Immune Signature for Head and Neck Cancer Prognosis

A six-gene immune-related signature stratifies prognosis and characterizes the tumor immune microenvironment in head and neck squamous cell carcinoma. Pian Li developed this signature using transcriptomic and clinical data from TCGA and GEO cohorts. The dataset was last updated in April 2026.

Use Cases

• Predict patient risk groups (high/low) using the six-gene signature (PYGL, SFRP1, FGD3, OLR1, DUSP9, MASP1) scores.
• Analyze associations between signature risk scores and clinical survival outcomes across multiple validation cohorts.
• Investigate correlations between the signature and tumor immune microenvironment features like immune infiltration scores or tumor mutation burden (TMB).
• Validate the signature's link to immunotherapy response prediction by comparing risk groups with reported response data.

Strengths

• Signature validated across four independent patient cohorts (TCGA and GEO).
• Derived from integrated transcriptomic and clinical data, linking gene expression to clinical outcomes.

Limitations

• Dataset size is only 14.7 KB, indicating it contains summary or model results, not the underlying raw patient-level data.
• Specific sample size (row count) and individual column definitions for clinical or expression features are unknown.

Provenance

Source

Integrated data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) cohorts.

Collection Method

Analysis involved unsupervised clustering, Cox regression, and LASSO regression to develop the prognostic signature.

Freshness

Last updated in April 2026.